MUC16 and ovarian carcinoma: Periodic follow-up measurements of CA-125 levels after treatment for ovarian cancer allow the detection of recurrences months before symptoms or signs appear, since the CA-125 level generally increases 2–6 months before a recurrence is radiologically or clinically detectable (39).